TrialCancer chemotherapy and pharmacology2020

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Rong Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.